The DOI matches its Crossref record.
Hematopoietic cell transplantation (HCT)-specific-comorbidity index: A new tool for risk assessment before allogeneic HCT
Open accessAbstract
We have reported on the use of Charlson comorbidity index (CCI) to predict non-relapse mortality (NRM) and overall survival (OS) for patients (pts) given nonablative or ablative HCT1. However, the sample size of pts with scores of ≥1, captured by the CCI, did not exceed 35%. Further, some of comorbidities were rarely found among pts given HCT. Therefore, we sought to develop an HCT-specific-comorbidity index aimed at a) better defining previously identified comorbidities, i.e. adding pulmonary functions tests to pulmonary, liver function tests to hepatic, and ejection fraction ≤50% to cardiac comorbidities and b) investigating additional HCT-related comorbidities. To this end, we retrospectively reviewed comorbidities of 1055 pts given HCT at our center between 1997–2003 after nonablative (n=294) or ablative (n=761) conditioning. Pts were randomly divided into training (n=708) and validation sets (n=347). In the training set, the unadjusted hazard ratios (HR) for 2-year NRM were calculated for each comorbidity and then adjusted for other comorbidities, disease risk, and conditioning type. The adjusted HRs were employed as weights for individual comorbidities. Differences encountered compared to the original CCI were: a) two new comorbidities were added (obesity= score 1 and peritransplantation infection= score 2), b) age ≥50 years acquired a score of 2, and c) hypertension and asthma each acquired a score of 1 instead of 0, moderate pulmonary, peptic ulcer, and rheumatologic each acquired a score of 2 instead of 1, valvular heart disease a score of 2 instead of 0, and severe pulmonary comorbidity a score of 3 instead of 1. In the training set, HR for NRM for scores 0, 1, 2, 3, 4, ≥5 were 1, 1.2, 3.5, 6.1, 7.1, and 10.8, respectively. The modified index was then validated using the validation set. This index had the advantage of 1) capturing more pts with high scores and 2) distinguishing pts with low scores who had lower NRM and better OS when compared to the original CCI (Table). Applying the scores to nonablative and ablative pts, respectively, NRM of 5 vs 10% (p=0.4) and OS of 85% vs 75% (p=0.1) were seen for scores of 0–1, 17 vs 27% (p=0.04) and 61 vs 59% (p=0.2) for scores of 2–3, and 33 vs 54% (p=0.03) and 43 vs 30% (p=0.006) for scores of ≥4. This HCT-specific comorbidity index provides a simple, readily applicable and valid method of estimating NRM and OS among pts given nonablative or ablative allogeneic HCT. (1. Sorror et al. Blood. 2004;104:961.)TablePercentages of pts and Two-Year Rates of NRM and OS in the Validation Set (n = 346) as Scored by the New HCT-Specific Comorbidity Index Compared to the Original CCIHCT-CIpts, %Two-Year RateOriginal CCIpts, %Two-Year RateNRM, %OS, %NRM, %OS, %0–137137205817642–33622581273351≥4274035≥2153141NRM indicates non-relapse mortality; OS, overall survival; CCI, Charlson comorbidity index; and HCT-CI, hematopoietic cell transplantation-specific comorbidity index. Open table in a new tab NRM indicates non-relapse mortality; OS, overall survival; CCI, Charlson comorbidity index; and HCT-CI, hematopoietic cell transplantation-specific comorbidity index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
El-Jawahri, A., LeBlanc, T., VanDusen, H., Traeger, L., Greer, J. A., Pirl, W. F., Jackson, V. A., Telles, J., Rhodes, A., Spitzer, T. R., et al. (2016) · JAMA · doi:10.1001/jama.2016.16786 · Cited by 392
Sorror, M. L., Sandmaier, B. M., Storer, B. E., Franke, G. N., Laport, G. G., Chauncey, T. R., Agura, E., Maziarz, R. T., Langston, A., Hari, P., et al. (2011) · JAMA · doi:10.1001/jama.2011.1558 · Cited by 320
Self-citationMalcovati, L., Della Porta, M. G., Strupp, C., Ambaglio, I., Kuendgen, A., Nachtkamp, K., Travaglino, E., Invernizzi, R., Pascutto, C., Lazzarino, M., et al. (2011) · Haematologica · doi:10.3324/haematol.2011.044602 · Cited by 282
Engelhardt, M., Domm, A.-S., Dold, S. M., Ihorst, G., Reinhardt, H., Zober, A., Hieke, S., Baayen, C., Müller, S. J., Einsele, H., et al. (2017) · Haematologica · doi:10.3324/haematol.2016.162693 · Cited by 274
Muffly, L. S., Kocherginsky, M., Stock, W., Chu, Q., Bishop, M. R., Godley, L. A., Kline, J., Liu, H., Odenike, O. M., Larson, R. A., et al. (2014) · Haematologica · doi:10.3324/haematol.2014.103655 · Cited by 255
Metadata
- Authors
- Sorror, M. L., Maris, M. B., Storb, R. F., Baron, F., Sandmaier, B. M., Maloney, D. G., & Barry, S. E.
- Venue
- Biology of Blood and Marrow Transplantation
- Publisher
- Elsevier BV
- Published
- 2005-02
- Volume
- 11
- Issue
- 2
- Pages
- 23-24
- ISSN
- 1083-8791 (ISSN-L)
- OpenAlex
- W1986730299
- Cited by
- 323
- References
- 0
- FWCI
- 2.14
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hematopoietic cell transplantation (HCT)-specific-comorbidity index: A new tool for risk assessment before allogeneic HCT. https://app.cochat.ai/papers/10.1016/j.bbmt.2004.12.067
- The paper
- Sorror, M. L., Maris, M. B., Storb, R. F., Baron, F., Sandmaier, B. M., Maloney, D. G., & Barry, S. E. (2005). Hematopoietic cell transplantation (HCT)-specific-comorbidity index: A new tool for risk assessment before allogeneic HCT. Biology of Blood and Marrow Transplantation. https://doi.org/10.1016/j.bbmt.2004.12.067
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.